Our Sr. Vice President of CMC and Process Development, Kara Calhoun, will moderate a panel on Monday, Sept. 30 at 4:00 - 4:45 pm ET at the? #FierceBiotechSummit in Boston. This panel of industry leaders will explore how biotech companies can strategically leverage CDMO partnerships to drive innovation, efficiency and success in drug development and manufacturing. ? Visit the event website to view the full agenda:? https://lnkd.in/gtM6CwrF ? See you in Boston! ?
NGM Biopharmaceuticals
生物技术研究
South San Francisco，CA 9,578 位关注者
Explorers on the frontier of life-changing science.
关于我们
NGM Bio is a biopharmaceutical company focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, always led by biology and motivated by unmet patient need. In addition to a healthy balance sheet and cash runway, the company currently has four programs in active clinical development. Visit us at www.ngmbio.com for more information.
- 网站
-
https://www.ngmbio.com
NGM Biopharmaceuticals的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- South San Francisco，CA
- 类型
- 上市公司
- 创立
- 2008
地点
-
主要
获取路线
333 Oyster Point Blvd.
US，CA，South San Francisco，94080
NGM Biopharmaceuticals员工
-
Lincoln Heacock
Fractional Chief Information Officer (CIO), Chief Technology Officer (CTO) & Chief Information Security Officer | Transformational Leader & Coach |…
-
Jean-Frederic Viret
-
Linda Tsang
Sr. Executive Administrator | C-Suite & BOD | Int'l Travel Mgmt | Arrange & Engage | Events Director | Financial Fluency | Tech Enthusiast
-
Connie Merron
Associate Director, Research Informatics
动态
-
We're thrilled to announce a?$122M Series A financing, led by The Column Group with participation from a select group of investors. Read press release: https://bit.ly/3LuwvU4 ? These funds will enable us to initiate a planned registrational trial of aldafermin for the treatment of primary sclerosing cholangitis and complete a planned Phase 2 proof-of-concept trial for the treatment of hyperemesis gravidarum (HG) - both expected to begin in Q4 2024.? ? PSC is a rare liver disease that irreparably damages the bile ducts, leading to bile acid dysregulation and, ultimately, severe liver damage. HG?is a rare, debilitating condition of pregnancy, characterized by intractable nausea and uncontrollable vomiting and frequent, serious complications.? ? There are no currently approved therapies for PSC or HG. #primarysclerosingcholangitis #hyperemesisgravidarum #hyperemesis
-
-
I'm hiring! Check out this opportunity if working in the People and Culture team is your passion, not just a job! https://lnkd.in/g7D5Mq9v
-
Today we were pleased to present positive Phase 2b results from the ALPINE 4 trial of aldafermin in patients with compensated cirrhosis (F4) due to #NASH at?American Association for the Study of Liver Diseases (AASLD) The Liver Meeting in Boston. #TLM23 ? Press release: https://bit.ly/40BAyES Presentation: https://bit.ly/47engAW
-
-
We're thrilled to announce today that Jean-Frederic Viret, Ph.D. has been appointed Chief Financial Officer of NGM Bio! Read more: https://bit.ly/49dVLc5
-